Featuring: The perfect sales outsourcing partnership // Does the Life Sciences Strategy over-promise? // How collaboration is transforming clinical research
Relationships can be tricky things – no more so than the pharma-contract sales organisation relationship. So, what are the secrets for making it a perfect match?
The proposed industrial strategy for the life sciences sector sets out some ambitious objectives – probably too ambitious, says Ana Nicholls
Allergy Therapeutics has begun dosing in a mid-stage trial designed to assess the dose-response and safety of its ultra-short course PQ Grass immunotherapy, which targets the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
19th October 2017
An alliance between industry and academia created by Cancer Research UK has discovered a new approach to targeting key cancer-linked proteins previously deemed ‘undruggable’.
19th October 2017
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German biotech.
19th October 2017
AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.
19th October 2017
Gilead’s Yescarta - recently acquired through its purchase of Kite Pharma - has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.
19th October 2017
Why UK expats in former British colonies are not missing the NHS
Why life sciences shouldn't overlook UX
Award-winning playwright Simon Vinnicombe’s baby son George was just six months old when he fell gravely ill with a shock diagnosis of type 1 diabetes. He talks to PharmaTimes about life with the disease and his hopes for a cure
The rise of open source search in pharma R&D
Ahead of the seventh Quality in Care (QiC) Diabetes awards in October, PharmaTimes speaks to judging chair and clinician Paru King to learn more about diabetes care in the UK
How to use your IP to get ahead of the game
EMIG chairman Leslie Galloway on the future of the pharma/NHS relationship
Paul Midgley and Steve How of Wilmington Healthcare explain how the NHS is rewarding its most promising STPs and what they need from pharma
Peter Taylor of the NIHR Translational Research Collaboration explains how the body is making the most of the industry’s pressing need for more joint working
The proposed industrial strategy for the life sciences sector sets out some ambitious objectives – probably too ambitious, says Ana Nicholls
The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.
Building better relationships based on partnership and collaboration creates more effective outcomes
Business development director at Star, Ryan Wooller, discusses commercial outsourcing and how the company has adapted to provide the best solutions as pharma companies look to innovate and reduce costs
Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
